NDA 021306 · Knoa Pharma
Butrans
Buprenorphine · Transdermal · Partial Opioid Agonist
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jun 30, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
512
125 Phase 3, 43 recruiting
FAERS reports
84,822
53,931 serious, 26,428 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM Addiction, Abuse, and Misuse Because the use of buprenorphine transdermal system exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine transdermal system, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of buprenorphine transdermal system are essential. Misuse or abuse of buprenorphine transdermal system by chewing, swallowing, snorting,...
What it is approved for
From the label in effect May 29, 2026.
Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including buprenorphine transdermal system, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic. Buprenorphine transdermal system is a partial opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including buprenorphine transdermal system for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic. ( 1 )
Mechanism: Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. The contributions of these actions to its analgesic profile are unclear.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 13, 2017 Supplement 27 · Efficacy LabelLetterPediatric Medical Review
- Jun 30, 2010 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLabel
5 products under this application
- BUTRANS · BUPRENORPHINE 15MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- BUTRANS · BUPRENORPHINE 10MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- BUTRANS · BUPRENORPHINE 7.5MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- BUTRANS · BUPRENORPHINE 20MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- BUTRANS · BUPRENORPHINE 5MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.
- Houston Emergency Opioid Engagement SystemEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03396276 · 3,000 participants (planned) · Start Apr 1, 2018 · Primary completion Aug 31, 2030
Drug: Suboxone · For: Opioid Use Disorder
Sites: Houston, Texas
- Emergency Department-Initiated Buprenorphine Validation Network TrialPivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT04225598 · 2,000 participants · Start Jul 8, 2020 · Primary completion Dec 6, 2024
Drug: CAM2038; Buprenorphine Sublingual Product · For: Opioid-use Disorder
Sites: Oakland, California; San Leandro, California; New Haven, Connecticut · 35 sites in all
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Pivotal-lookingActive, not recruiting
NYU Langone HealthAcademic, hospital or other
NCT04464980 · 1,516 participants · Start Jun 8, 2021 · Primary completion Dec 31, 2026
Drug: SL-BUP; XR-BUP and 1 more · For: Opioid Use Disorder (OUD)
Sites: Little Rock, Arkansas; Tarzana, California; Bridgeport, Connecticut · 21 sites in all
- Buprenorphine and Integrated HIV Care EvaluationStatus unknown
The New York Academy of MedicineAcademic, hospital or other
NCT00124358 · 1,350 participants · Start Aug 2005
Drug: Buprenorphine · For: Opioid-Related Disorders; HIV Infections; AIDS
Sites: Tucson, Arizona; Oakland, California; San Francisco, California · 10 sites in all
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug UsersPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00270257 · 1,251 participants · Start May 2008 · Primary completion Jul 2012
Drug: Buprenorphine/Naloxone · For: HIV Infections; Opioid-Related Disorders
Sites: Hengzhou Town, China; Nanning, China; Ürümqi, China · 4 sites in all
- Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Braeburn PharmaceuticalsIndustry
NCT02946073 · 1,053 participants · Start Sep 2016 · Primary completion May 2018
Drug: buprenorphine · For: Chronic Lower Back Pain; Chronic Pain
Sites: Birmingham, Alabama; Hamilton, Alabama; Vestavia Hills, Alabama · 69 sites in all
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use DisorderPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT04375033 · 952 participants (planned) · Start Nov 3, 2020 · Primary completion Sep 30, 2028
Drug: Sublingual buprenorphine with naloxone; Injectable subcutaneous buprenorphine · For: Opioid Use Disorder
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Long Beach, California · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death13,389
- drug dependence12,078
- overdose10,916
- toxicity to various agents10,759
- pain8,180
- drug ineffective6,221
- drug withdrawal syndrome5,754
- emotional distress5,448
- nausea4,248
- drug abuse3,588
- inadequate analgesia3,049
- application site rash3,025
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 34 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 37 |
| 2010 | 96 |
| 2011 | 426 |
| 2012 | 667 |
| 2013 | 13,502 |
| 2014 | 5,252 |
| 2015 | 4,559 |
| 2016 | 3,033 |
| 2017 | 4,504 |
| 2018 | 22,273 |
| 2019 | 2,613 |
| 2020 | 3,991 |
| 2021 | 8,152 |
| 2022 | 5,243 |
| 2023 | 2,351 |
| 2024 | 2,866 |
| 2025 | 3,245 |
| 2026 | 1,966 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Butrans (Buprenorphine)
2024 spending
$10.8M
Beneficiaries
5,870
25,786 claims
Per beneficiary
$1,840
$102.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $36,897,930 |
| 2021 | $28,027,195 |
| 2022 | $24,817,188 |
| 2023 | $23,248,673 |
| 2024 | $10,800,854 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials.
Hickey TR, Costa GPA, Oliveira D, et al. · Reg Anesth Pain Med 2026 · Systematic Review, Meta-Analysis
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, et al. · Lancet Psychiatry 2023 · Meta-Analysis, Systematic Review
- Pharmacy-based expansion of buprenorphine access.
Clark SA, Green TC, Rich JD · J Subst Use Addict Treat 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. · BMJ 2017 · Meta-Analysis, Systematic Review
- Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.
D'Onofrio G, Herring AA, Hawk KF, et al. · JAMA 2026 · Clinical Trial, Phase II, Comparative Study
- Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR, Walsh SL, Nunes EV, et al. · JAMA Intern Med 2018 · Comparative Study, Randomized Controlled Trial
Sponsor: Knoa Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.